Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1539820
Reference Type
Journal Article
Title
Impact of Sublingual Sildenafil on Pulmonary Hypertension in Patients with Heart Failure
Author(s)
Figueiredo de Freitas, A, Jr; Bacal, F; Oliveira, J, Jr; Barros Santos, RH; Pinho Moreira, LF; Silva, CP; Mangini, S; Dias Carneiro, RM; Fiorelli, AI; Bocchi, EA
Year
2009
Is Peer Reviewed?
0
Journal
Arquivos Brasileiros de Cardiologia
ISSN:
0066-782X
EISSN:
1678-4170
Volume
92
Issue
2
Page Numbers
122-126
Web of Science Id
WOS:000265050600008
Abstract
Pulmonary hypertension (PH) is a factor of poor prognosis
in the postoperative period of heart transplant (HT) and thus, the study of the degree of
reversibility to vasodilators is mandatory during the preoperative assessment. To evaluate the
pulmonary and systemic hemodynamic effects of sildenafil as a vasodilator during the PH
reversibility test in patients that are candidates to HT. Patients awaiting HT were submitted to
the measurement of systemic and pulmonary hemodynamic variables before and after the
administration of a single sublingual dose of 100 mg of sildenafil during right heart
catheterization. Fourteen patients (age: 47 +/- 12 years, 71.4% men) with advanced heart failure
Ejection Fraction (EF) 25 +/- 7%, Functional Class (FC - NYHA) FC III - 6 and FC IV - 8, were
evaluated in this study. The acute administration of sildenafil showed to be effective in
decreasing the systolic (62.4 +/- 12.1 vs. 51.5 +/- 9.6 mmHg, CI=95%, p<0.05) and mean (40.7 +/-
7.3 vs. 33.8 +/- 7.6 mmHg, CI=95%, p <0.05) pressures of the pulmonary artery. There was also a
significant decrease in the pulmonary (4.2 +/- 3 vs. 2.0 +/- 0.9 uWood, CI=95%, p<0.05) and
systemic vascular resistance (22.9 +/- 6.8 vs. 18.6 +/- 4.1 Wood, CI=95 %, p<0.05), associated to
an increase in the cardiac output (3.28 +/- 0.79 vs. 4.12 +/- 1.12 uWood, CI=95%, p<0.05)
without, however, significantly interfering in the systemic arterial pressure (87.8 +/- 8.2 vs.
83.6 +/- 9.1 mmHg, CI=95%, p=0.3). The sublingual administration of sildenafil is an effective
and safe alternative as a vasodilator during the PH reversibility test in patients with heart
failure and awaiting a HT. (Arq Bras Cardiol 2009; 92(2): 116-120)
Keywords
Vasodilatator agents; hypertension, pulmonary; heart failure
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity